Globus Medical Slides 8% as Revenue Guidance Holds Steady, Nevro Challenges Cited
summarizeSummary
Globus Medical's stock slid 8.3% after the company reaffirmed its full-year revenue guidance, despite reporting strong first-quarter results and raising its full-year adjusted EPS guidance. This follows the company's Q1 2026 earnings report yesterday, which showed significant beats on both revenue ($759.9M vs. $740.3M expected) and adjusted EPS ($1.12 vs. $0.92 expected). The market appears to be reacting negatively to the company's decision to hold its full-year revenue guidance steady at $3.18 billion to $3.22 billion, which was in line with analyst expectations but perhaps below investor hopes for an upward revision. Management cited strategic changes in its Enabling Technology division and ongoing revenue challenges with the Nevro business, including a 17% decline in Nevro's contribution from Q4 2025, as reasons for not raising revenue guidance. Investors will be monitoring the performance of the Nevro business and the impact of strategic changes, as these factors are directly influencing the company's revenue outlook, despite the positive signal from the raised full-year adjusted EPS guidance to $4.70-$4.80.
At the time of this announcement, GMED was trading at $78.32 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.6B. The 52-week trading range was $51.79 to $101.40. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.